- Busy M&A activity sets tone as biopharma earnings season kicks offWith the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry: Will the good times continue? The answer to that…Endpoints · 14d ago↗ source
- Building a workforce engine for biomanufacturingOhio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.Fierce Biotech · 14d ago↗ source
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necess…Endpoints · 14d ago